Immunome, Inc. Hits Day High with Strong 8.09% Intraday Surge

Immunome, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable surge in its stock price, gaining 8.09% on September 23, 2025. The stock reached an intraday high of USD 10.73, reflecting a strong performance relative to the broader market. Over the past day, Immunome's performance outpaced the S&P 500, which only saw a 0.44% increase.
In the past week, Immunome has shown a 14.04% rise, while its monthly performance stands at an impressive 41.55%. However, the stock has faced challenges over the past year, with a decline of 34.21%, contrasting sharply with the S&P 500's 17.38% gain. Despite these fluctuations, the company has reported positive results after five consecutive quarters of losses, with a net profit of USD -85.04 million and a significant reduction in raw material costs.

Institutional holdings remain robust at 100%, indicating strong confidence from larger investors. While the stock has underperformed in the last year, its three-year performance shows a remarkable increase of 213.35%, suggesting potential resilience in the long term.